TMB and various biomarkers were positively associated with improved pCR and EFS in high-risk, early-stage TNBC, regardless of ...

BI-1910 single agent Phase 1 Part A dose escalation has been completed and reached a biologically active dose level. Data ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

The SU2C-SARC032 study demonstrated that pembrolizumab combined with radiotherapy and surgery was well tolerated, with ...

Pembrolizumab biosimilar is under clinical development by Formycon and currently in Phase III for Non-Small Cell Lung Cancer.

When Carter was diagnosed with metastatic melanoma, he told the country he'd be trying a new cutting-edge cancer treatment - ...

Lenvatinib plus pembrolizumab did not improve PFS or OS over chemotherapy in patients with advanced or recurrent endometrial ...

Multi-centre trial evaluating efti in combination with pembrolizumab and chemotherapy in patients with non-small cell lung cancer reaches ...

Potential practice-changing therapies in gynecologic cancer include the emergence of carboplatin, paclitaxel, and PD-1 ...

The immune checkpoint inhibitor pembrolizumab may reduce this risk. New research findings are summarized in a short video.

The following is a summary of “Neoadjuvant Pembrolizumab in Stage I-III Deficient Mismatch Repair Colon Cancer: A Clinical ...